Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207
June 17 2014 - 10:00AM
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report
new data supporting the positive sexual functional preservation
profile of NX-1207, the Company's lead compound in Phase 3
development for the treatment of prostate enlargement (BPH or
benign prostatic hyperplasia) and Phase 2 development for localized
prostate cancer. A detailed study of prostate tissues from men who
had received intraprostatic injections of NX-1207 2.5 mg or 15 mg
found that nervous tissues in the prostate after treatment were
left intact and showed no damage. These new results showing that
NX-1207 is nerve-sparing add to the considerable body of evidence
that treatment with NX-1207 does not lead to the debilitating
sexual side effects often associated with existing prostate
treatments.
Men who receive surgical or drug treatments for BPH or prostate
cancer, not uncommonly suffer sexual side effects of a permanent
nature. These long term effects can include impotence, retrograde
ejaculation, loss of libido, and other disorders. For this reason,
men are often reluctant to seek necessary treatment or to continue
with drug therapy.
The nerve-sparing findings are consistent with results from
earlier studies which have shown evidence of sexual functional
preservation in men after NX-1207 treatment, including 1) patient
reports of no significant new clinical sexual problems, 2) no
change in blood testosterone levels, and 3) sexual function
questionnaire data showing no sexual side effects from NX-1207
treatment.
NX-1207 is a novel patented drug developed by Nymox that is
administered by a urologist in an office setting directly into the
zone of the prostate to be treated. The procedure takes only a few
minutes, does not require sedation, anesthesia or catheterization,
and involves little or no pain or discomfort.
NX-1207 successfully completed a series of blinded controlled
multi-center U.S. clinical trials for BPH where a single 2.5 mg
dose of NX-1207 was found to produce at 90 days an average
improvement in standardized symptom score about double that
reported for currently approved BPH drugs without causing the
sexual or cardiovascular side effects associated with those drugs.
Follow-up studies showed evidence of long lasting benefit with a
significant proportion of men who received a single dose reporting
maintained improvement in BPH symptoms without other treatments for
up to 5 years or more.
Nymox recently announced the completion of its second pivotal
Phase 3 trial of NX-1207 for BPH, NX02-0018, and top-line results
for its Phase 2 trial of NX-1207 for localized low risk prostate
cancer, NX03-0040.
BPH is one of the most commonly diagnosed diseases in older men.
The condition can have a significant negative impact on a man's
health and quality of life and can lead to acute urinary retention,
incontinence and other serious consequences. It is estimated that
50% of men in their 50s have pathological signs of prostatic
hyperplasia and from 26 to 46% of men between the ages of 40 to 79
years suffer from moderate to severe urinary problems and symptoms
associated with BPH.
More information about Nymox is available at www.nymox.com,
email: info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements"
as defined in the United States Private Securities Litigation
Reform Act of 1995 that involve a number of risks and
uncertainties. There can be no assurance that such statements will
prove to be accurate and the actual results and future events could
differ materially from management's current expectations. Such
factors are detailed from time to time in Nymox's filings with the
United States Securities and Exchange Commission and other
regulatory authorities.
CONTACT: Brian Doyle
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Sep 2023 to Sep 2024